Intra-arterial administration of verapamil for prevention and treatment of cerebral angiospasm after SAH due to cerebral aneurysm rupture
Микеладзе К. Г., Окишев Д. Н., Белоусова О. Б., Коновалов А. Н., Пилипенко Y. В., Хеиреддин А. С., Агеев И. С., Шехтман О. Д., Курдюмова Н. В., Табасаранскиy Т. Ф., Окишева Е. А., Елиава С. С., Яковлев С. Б.
Вопросы нейрохирургии им. Н.Н. Бурденко
Т. 82, Вып. 4, С. 23-31
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.17116/neiro201882423
Аннотация:
Aim — the study purpose was to analyze the efficacy of intra-arterial administration of verapamil (IAV) in the treatment of angiospasm in SAH patients and to determine optimal parameters of the procedure. A number of studies demonstrated the efficacy of intra-arterial administration of vasodilators, in particular verapamil, in the treatment of angiospasm after aneurysmal SAH, which served the basis for inclusion of this method in the recommended protocol for treatment of SAH patients [1―7]. Material and methods. We analyzed the efficacy of IAV in 35 patients in the acute period of SAH, with 77.2[%] of the patients having a Hunt-Hess score of III―V. The inclusion criteria were as follows: IAV within two weeks after SAH; excluded aneurysm; verapamil dose per administration of at least 15 mg; follow-up for at least three months. Efficacy endpoints were as follows: changes in spasm according to angiography and transcranial dopplerography (TCDG); development of ischemic lesions; clinical outc
Ключевые слова:
Angiospasm treatment; Intra-arterial administration of verapamil; SAH
vasodilator agent; verapamil; aneurysm rupture; brain angiography; brain vasospasm; complication; diagnostic imaging; female; human; intraarterial drug administration; intracranial aneurysm; male; middle aged; retrospective study; subarachnoid hemorrhage; treatment outcome; x-ray computed tomography; Aneurysm, Ruptured; Cerebral Angiography; Female; Humans; Infusions, Intra-Arterial; Intracranial Aneurysm; Male; Middle Aged; Retrospective Studies; Subarachnoid Hemorrhage; Tomography, X-Ray Computed; Treatment Outcome; Vasodilator Agents; Vasospasm, Intracranial; Verapamil
Язык текста: Русский
ISSN: 2309-1681
Микеладзе К. Г.
Окишев Д. Н.
Белоусова О. Б.
Коновалов А. Н.
Пилипенко Y. В.
Хеиреддин А. С.
Агеев И. С.
Шехтман О. Д.
Курдюмова Н. В.
Табасаранскиy Т. Ф.
Окишева Е. А. Елена Андреевна 1983-
Елиава С. С.
Яковлев С. Б.
Mikeladze K. G.
Okishev D. N.
Belousova O. B.
Konovalov A. N.
Pilipenko Y. V.
Kheireddin A. S.
Ageev I. S.
Shekhtman O. D.
Kurdyumova N. V.
Tabasaranskiy T. F.
Okisheva E. A. Elena Andreevna 1983-
Eliava S. S.
Yakovlev S. B.
Intra-arterial administration of verapamil for prevention and treatment of cerebral angiospasm after SAH due to cerebral aneurysm rupture
Текст визуальный непосредственный
Вопросы нейрохирургии им. Н.Н. Бурденко
Издательство Медиа Сфера
Т. 82, Вып. 4 С. 23-31
2018
Статья
Angiospasm treatment Intra-arterial administration of verapamil SAH
vasodilator agent verapamil aneurysm rupture brain angiography brain vasospasm complication diagnostic imaging female human intraarterial drug administration intracranial aneurysm male middle aged retrospective study subarachnoid hemorrhage treatment outcome x-ray computed tomography Aneurysm, Ruptured Cerebral Angiography Female Humans Infusions, Intra-Arterial Intracranial Aneurysm Male Middle Aged Retrospective Studies Subarachnoid Hemorrhage Tomography, X-Ray Computed Treatment Outcome Vasodilator Agents Vasospasm, Intracranial Verapamil
Aim — the study purpose was to analyze the efficacy of intra-arterial administration of verapamil (IAV) in the treatment of angiospasm in SAH patients and to determine optimal parameters of the procedure. A number of studies demonstrated the efficacy of intra-arterial administration of vasodilators, in particular verapamil, in the treatment of angiospasm after aneurysmal SAH, which served the basis for inclusion of this method in the recommended protocol for treatment of SAH patients [1―7]. Material and methods. We analyzed the efficacy of IAV in 35 patients in the acute period of SAH, with 77.2[%] of the patients having a Hunt-Hess score of III―V. The inclusion criteria were as follows: IAV within two weeks after SAH; excluded aneurysm; verapamil dose per administration of at least 15 mg; follow-up for at least three months. Efficacy endpoints were as follows: changes in spasm according to angiography and transcranial dopplerography (TCDG); development of ischemic lesions; clinical outc